C Rottenburger, M Hentschel, T Kelly… - Clinical Nuclear …, 2011 - journals.lww.com ... Limitations of the method, caused by an overlap between viable tumor in brainmetastases and necrosis, have been reported. 7 These authors reported lower LNRs for MET in cases of recurrence of metastaticbraintumor, compared with recurrence of gliomas. ... Related articles - All 3 versions
WT Chiu, HT Lee, FJ Huang, KD Aldape, J Yao… - Cancer Research, 2011 - AACR ... Inhibition Breast Tumor Growth and BrainMetastases by Stat3 Caveolin-1 Upregulation Mediates Suppression of Primary ...Brainmetastases Breast tumor cells (3 Â 105) were slowly injected into the intracarotid artery of nude mice. ... Related articles - All 2 versions
B Gril, D Palmieri, Y Qian, DD Smart, L Ileva… - Clinical Cancer …, 2011 - AACR Results: Treatment with 100 mg/kg of pazopanib resulted in a 73% decline in large 231-BR-HER2 metastases (P < 0.0001) and a 39% decline in micrometastases (P = 0.004). In vitro, pazopanib was directly antiproliferative to 231-BR-HER2 breast cancer cells and inhibited MEK and ... Cited by 4 - Related articles - All 4 versions
EC Woodhouse… - Cancer Metastasis: Biologic Basis and …, 2011 - books.google.com ... Oncogene. 19: 3706–3716. Beaucher M, Goodliffe J, Hersperger E, Trunova S, Frydman H, Shearn A (2007a) Drosophila braintumormetastases express both neuronal and glial cell type markers. Dev Biol. 301: 287–297. Beaucher ... Related articles
…, T Bachelot, S Delaloge, E Brain… - Annals of …, 2011 - Eur Soc Med Oncology Results: Baseline CTC detection rate was 65% with ≥1 CTC/7.5 ml threshold and 44% with ≥5 CTC/7.5 ml and was independent of subtypes (luminal, triple negative, human epithelial growth factor receptor 2 (HER2)+). CTCs were associated with tumor markers, bone/liver ... Related articles - All 2 versions
C Rottenburger, M Hentschel, T Kelly… - Clinical Nuclear …, 2011 - journals.lww.com ... Limitations of the method, caused by an overlap between viable tumor in brainmetastases and necrosis, have been reported. 7 These authors reported lower LNRs for MET in cases of recurrence of metastaticbraintumor, compared with recurrence of gliomas. ... Related articles - All 3 versions
WT Chiu, HT Lee, FJ Huang, KD Aldape, J Yao… - Cancer Research, 2011 - AACR ... Inhibition Breast Tumor Growth and BrainMetastases by Stat3 Caveolin-1 Upregulation Mediates Suppression of Primary ...Brainmetastases Breast tumor cells (3 Â 105) were slowly injected into the intracarotid artery of nude mice. ... Related articles - All 2 versions
B Gril, D Palmieri, Y Qian, DD Smart, L Ileva… - Clinical Cancer …, 2011 - AACR Results: Treatment with 100 mg/kg of pazopanib resulted in a 73% decline in large 231-BR-HER2 metastases (P < 0.0001) and a 39% decline in micrometastases (P = 0.004). In vitro, pazopanib was directly antiproliferative to 231-BR-HER2 breast cancer cells and inhibited MEK and ... Cited by 4 - Related articles - All 4 versions
EC Woodhouse… - Cancer Metastasis: Biologic Basis and …, 2011 - books.google.com ... Oncogene. 19: 3706–3716. Beaucher M, Goodliffe J, Hersperger E, Trunova S, Frydman H, Shearn A (2007a) Drosophila braintumormetastases express both neuronal and glial cell type markers. Dev Biol. 301: 287–297. Beaucher ... Related articles
…, T Bachelot, S Delaloge, E Brain… - Annals of …, 2011 - Eur Soc Med Oncology Results: Baseline CTC detection rate was 65% with ≥1 CTC/7.5 ml threshold and 44% with ≥5 CTC/7.5 ml and was independent of subtypes (luminal, triple negative, human epithelial growth factor receptor 2 (HER2)+). CTCs were associated with tumor markers, bone/liver ... Related articles - All 2 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
